David B Kaye, MD, INC
David B Kaye, MD, INC was paid $1.08M by Medicaid between Jan 2018 and Nov 2024, across 35 billing codes. Its largest line is 66984, Extracapsular cataract removal with insertion of intraocular lens prosthesis — 16% of everything it billed.
33Billing provider infoDAVID B KAYE, MD, INC
FRESNO, CA 93710
FRESNO, CA 93710
33aNPI1811068455assigned 11/13/2006
33bProvider typeOptometrist
28Total paid$1.08M
24GClaims134,632
24DCodes billed35
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Optometrist providers in California
Rank by total paid#62 of 1,899
Median peer was paid$23K
This provider vs. median48×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,485 | $132K | |
| 2019 | 15,638 | $154K | |
| 2020 | 16,342 | $136K | |
| 2021 | 18,294 | $139K | |
| 2022 | 21,050 | $174K | |
| 2023 | 26,508 | $173K | |
| 2024incomplete | 21,315 | $175K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 16% | 2,335 | 2,032 | $178K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 26,251 | 24,610 | $135K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | 12% | 4,191 | 4,182 | $126K |
| V2020 | Frames, purchases | 9.0% | 5,670 | 5,663 | $97K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 8.7% | 3,742 | 3,725 | $95K |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | 7.3% | 4,498 | 4,490 | $79K |
| 67028 | Intravitreal injection of a pharmacologic agent | 5.6% | 4,033 | 3,526 | $60K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.0% | 18,343 | 17,416 | $54K |
| 92015 | Determination of refractive state | 4.3% | 7,249 | 7,230 | $47K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 4.0% | 4,835 | 4,803 | $43K |
| 92250 | 3.8% | 16,043 | 15,742 | $41K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.2% | 3,448 | 3,337 | $24K |
23 more codes
| 92341 | 1.7% | 820 | $18K | |
| J9035 | Injection, bevacizumab, 10 mg | 1.5% | 3,512 | $16K |
| 92133 | 1.3% | 5,927 | $14K | |
| 92134 | 1.2% | 6,649 | $13K | |
| 92020 | <1% | 7,565 | $11K | |
| 92136 | <1% | 2,610 | $9K | |
| 76512 | <1% | 1,882 | $7K | |
| 67228 | <1% | 276 | $6K | |
| 66761 | <1% | 230 | $4K | |
| 92083 | <1% | 3,229 | $4K | |
| 67031 | <1% | 68 | $1K | |
| 76514 | <1% | 856 | $780.42 | |
| 65875 | <1% | 30 | $392.03 | |
| 65855 | <1% | 17 | $388.00 | |
| 92132 | <1% | 100 | $330.65 | |
| 92273 | <1% | 33 | $122.88 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 56 | $71.43 |
| 99243 | <1% | 13 | $64.91 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 51 | $38.26 |
| 92285 | 0% | 32 | $0.00 | |
| 92275 | 0% | 12 | $0.00 | |
| 99024 | 0% | 13 | $0.00 | |
| 68200 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKAYE, DAVID (CEO)